Residual Solvent Testing for SGLT2 Inhibitor APIs: Standards, Methods, and Regulatory Compliance

Residual solvent testing is an essential quality control requirement for SGLT2 inhibitor active pharmaceutical ingredients (APIs) such as dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin. Because these aryl C-glucoside drug substances are manufactured through multi-step syntheses that employ Class 2 and Class 3 organic solvents, manufacturers must demonstrate that residual levels comply with ICH Q3C limits using validated headspace gas chromatography methods. This technical article reviews the regulatory framework, analytical procedures, acceptance criteria, and practical considerations for residual solvent analysis of SGLT2 inhibitor APIs.

Technical Overview

SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) are an important class of oral antidiabetic drugs that reduce renal glucose reabsorption and improve cardiovascular and renal outcomes in patients with type 2 diabetes. Marketed and pipeline compounds in this class include dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, ipragliflozin, sotagliflozin, bexagliflozin, and remogliflozin. Structurally, these molecules are aryl C-glucosides produced through multi-step synthetic routes involving glycosylation, metal-catalyzed coupling, halogenation, deprotection, and crystallization steps.

These synthetic processes make extensive use of organic solvents such as dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP), acetonitrile, methanol, ethanol, isopropanol, acetone, ethyl acetate, methyl tert-butyl ether (MTBE), tetrahydrofuran (THF), toluene, dichloromethane, hexane, and heptane. Solvents that are not completely removed by drying, washing, or crystallization remain in the final API as residual solvents, which carry potential toxicity risks and must therefore be strictly controlled.

Residual solvent control for SGLT2 inhibitor APIs is governed by internationally harmonized guidelines, including:

• ICH Q3C (R8) Impurities: Guideline for Residual Solvents
• USP General Chapter 467, Residual Solvents
• European Pharmacopoeia 2.4.24, Identification and Quantification of Residual Solvents
• Chinese Pharmacopoeia General Chapter 0861, Residual Solvent Determination

ICH Q3C classifies solvents into three categories based on toxicity: Class 1 solvents should be avoided, Class 2 solvents must be limited to protect patient safety, and Class 3 solvents have low toxic potential and may be controlled by less rigorous approaches. Analytical results are reported in parts per million (ppm) and compared against permissible concentration limits calculated from permitted daily exposure (PDE) values.

Testing Samples

Dapagliflozin API

Dapagliflozin drug substance is typically monitored for process-related residual solvents such as acetonitrile, ethanol, isopropanol, toluene, DMSO, MTBE, dichloromethane, and ethyl acetate, depending on the synthetic route and final crystallization solvent system used by the manufacturer. Both the API and its key intermediates can be submitted for evaluation.

Empagliflozin API

Reported manufacturing routes for empagliflozin employ solvents including toluene, THF, acetonitrile, methanol, ethanol, and acetone. Residual solvent profiling should reflect the actual route of synthesis documented in the drug master file (DMF) or process chemistry records.

Canagliflozin API

Canagliflozin synthesis commonly involves toluene, THF, hexane or heptane, acetonitrile, methanol, and dichloromethane. Testing panels are customized to include all solvents used in the final synthetic steps and purification operations, where carryover risk is highest.

Ertugliflozin, Ipragliflozin, and Other SGLT2 Inhibitors

Newer and regionally marketed SGLT2 inhibitors, including ertugliflozin, ipragliflozin, sotagliflozin, and bexagliflozin, are evaluated on a case-by-case basis. Target solvent lists are established after reviewing the synthesis route, and typically include a combination of polar aprotic solvents, alcohols, esters, and hydrocarbons.

Intermediates and Starting Materials

Although ICH Q3C limits formally apply to the drug substance, residual solvent data on key intermediates provide early process understanding, support purge studies, and justify skip-testing or reduced testing strategies in the control strategy.

Testing Items

The residual solvent panel for an SGLT2 inhibitor API is derived from the synthesis route and typically includes the following categories:

Class 1 Solvents (To Be Avoided)

• Benzene (limit: 2 ppm)
• Carbon tetrachloride (limit: 4 ppm)
• 1,2-Dichloroethane (limit: 5 ppm)
• 1,1-Dichloroethene (limit: 8 ppm)
• 1,1,1-Trichloroethane (limit: 1500 ppm)

Class 2 Solvents (Commonly Relevant to SGLT2 Inhibitor Processes)

• Methanol (limit: 3000 ppm)
• Acetonitrile (limit: 410 ppm)
• Dichloromethane (limit: 600 ppm)
• Hexane (limit: 290 ppm)
• Toluene (limit: 890 ppm)
• Tetrahydrofuran (limit: 720 ppm)
• N,N-Dimethylformamide (limit: 880 ppm)
• N-Methylpyrrolidone (limit: 530 ppm)
• Pyridine (limit: 200 ppm)
• Chloroform (limit: 60 ppm)
• Chlorobenzene (limit: 360 ppm)
• Xylenes (limit: 2170 ppm)
• 1,4-Dioxane (limit: 380 ppm)

Class 3 Solvents (Low Toxic Potential)

Class 3 solvents carry a general concentration limit of 5000 ppm and include ethanol, isopropanol, acetone, ethyl acetate, methyl tert-butyl ether, DMSO, heptane, 1-propanol, propyl acetate, and ethyl ether, among others. These solvents are frequently used in the final crystallization and drying steps of SGLT2 inhibitor manufacture.

Testing Methods

Sample Preparation

SGLT2 inhibitor APIs are glucosides with limited aqueous solubility. Samples are accurately weighed (typically 100 to 500 mg) into headspace vials and dissolved in a suitable diluent such as DMSO, DMF, or dimethylacetamide. Matrix-matched external standards are prepared at the ICH Q3C concentration limits for each target solvent.

Static Headspace Gas Chromatography with Flame Ionization Detection (HS-GC-FID)

The primary screening technique follows the harmonized pharmacopeial procedure (USP 467, Ph. Eur. 2.4.24, and ChP 0861) using static headspace GC-FID. Representative conditions include:

• Column: USP G43 phase, 6% cyanopropyl phenyl and 94% dimethylpolysiloxane, 30 m × 0.32 mm, 1.8 µm film (Procedure A)
• Carrier gas: helium or nitrogen with appropriate linear velocity
• Oven program: 40°C held for 20 minutes, ramped at 10°C/min to 240°C, then held
• Injection: split mode (approximately 1:5), inlet temperature 140°C
• Detector: FID at 250°C with hydrogen and air
• Headspace conditions: vial equilibration at 80°C for 30 to 45 minutes, with heated loop and transfer line to prevent condensation

Confirmation and Quantification

If a peak is observed in Procedure A that exceeds the acceptable limit, identity is confirmed on an alternative stationary phase such as a USP G16 polyethylene glycol column (Procedure B). Quantification is then performed against matrix-matched standards (Procedure C or an equivalent validated approach) to determine the actual concentration in ppm. For routine batch release, many laboratories develop product-specific, fully validated HS-GC-FID methods with optimized resolution and sensitivity for the route-specific solvent panel.

Method Validation

Product-specific methods are validated in accordance with ICH Q2(R2), covering the following attributes:

• Specificity: resolution of each target solvent from adjacent peaks and from the sample matrix diluent
• Linearity: typically over a range from the quantitation limit to 150% or 200% of the specification, with correlation coefficient not less than 0.99
• Accuracy: recovery typically within 80% to 120% at the limit level
• Precision: repeatability and intermediate precision with RSD generally not more than 10%
• Limit of detection and limit of quantitation: sufficient to control levels well below the ICH limits
• Robustness: deliberate variations in headspace temperature, equilibration time, oven ramp rate, and split ratio
• Solution stability and headspace carryover assessment

Reporting and Acceptance Criteria

Results are reported in ppm for each solvent and compared against the ICH Q3C concentration limits or tighter in-house specifications where justified. Any out-of-specification result triggers a structured laboratory investigation, including a review of sample preparation, headspace saturation effects, and possible retesting in accordance with pharmacopeial provisions.

Applications

Residual solvent testing for SGLT2 inhibitor APIs supports the full product lifecycle and is applied in the following contexts:

• Routine batch release testing of commercial and clinical drug substance
• Regulatory submissions, including DMFs, ASMFs, ANDAs, and NDAs with CMC documentation
• Process development, solvent selection, and drying or crystallization optimization studies
• Method transfer and bridge studies between development and commercial laboratories
• Purge studies and control strategy justification for reduced or skip testing
• Stability programs confirming that residual solvent levels remain within limits over the shelf life
• Supplier qualification and comparability studies for API sourced from multiple manufacturers

FAQ

Question: Why is residual solvent testing required for SGLT2 inhibitor APIs?

Answer: Solvents used in synthesis that are not fully removed may remain in the drug substance at toxicologically significant levels. ICH Q3C and the major pharmacopeias require manufacturers to demonstrate that residual solvent levels in the final API are within safe limits to protect patients, and this data is a mandatory element of regulatory filings and batch release.

Question: Which method should be used, the pharmacopeial method or a product-specific method?

Answer: The harmonized pharmacopeial headspace GC-FID procedure (USP 467, Ph. Eur. 2.4.24, or ChP 0861) is suitable for routine screening of most solvents. A product-specific validated method is recommended when the matrix causes interference, when route-specific solvents are not adequately resolved, or when a sponsor requires optimized sensitivity for regulatory filing.

Question: Can Class 3 solvents be controlled without gas chromatography?

Answer: If the manufacturing process uses only Class 3 solvents, ICH Q3C permits control by loss on drying or other suitable analytical techniques, provided the approach is scientifically justified. When Class 2 or Class 1 solvents are also present, GC-based testing remains necessary.

Question: How much sample is required for testing?

Answer: Typically 1 to 5 grams of API is sufficient for a full residual solvent panel, including any required confirmation testing. Additional sample may be requested to cover repeat or investigation testing.

Question: What is a typical turnaround time?

Answer: Standard testing using an established method is generally completed within 5 to 10 business days. Projects requiring new method development and full validation require additional time and are scoped individually.

Question: How are results interpreted against specifications?

Answer: Each reported solvent concentration in ppm is compared with the applicable ICH Q3C limit or an approved in-house specification. Results below the limit conform; any excursion requires investigation, assessment of batch disposition, and, where necessary, corrective action in the manufacturing process.